| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Terracotta, Inc. is a computer software company that specializes in increasing scalability, availability, and performance of real-time Big Data applications.
The worlds leading activity and venue management software for rental karting, trampoline and family entertainment centers.
Keeping up with the latest technology improvements, and the costs of managing them, can be very demanding. At NewPush, our mission is to make the latest improvements accessible and cost-effective. Instead of adding more headcount and purchasing more eq...